Loading...
XNASMDWD
Market cap192mUSD
Dec 24, Last price  
17.89USD
1D
1.25%
1Q
5.30%
Jan 2017
-44.19%
IPO
-85.93%
Name

Mediwound Ltd

Chart & Performance

D1W1MN
XNAS:MDWD chart
P/E
—
P/S
10.33
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.40%
Rev. gr., 5y
40.60%
Revenues
19m
-29.48%
000259,000601,0001,558,0002,496,0003,401,00031,789,00021,763,00023,763,00026,496,00018,686,000
Net income
-7m
L-65.73%
-6,169,00010,940,000-15,351,000-18,875,000-22,088,000-18,885,000-22,149,000-1,057,0003,718,000-9,601,000-13,551,000-19,599,000-6,716,000
CFO
-10m
L-11.95%
-2,960,000-4,728,000-9,740,000-16,493,000-19,601,000-16,445,000-16,455,000-12,154,0008,289,000-6,895,000-8,916,000-11,885,000-10,465,000
Earnings
Mar 19, 2025

Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
URL
https://www.mediwound.com/
IPO date
Mar 20, 2014
Employees
83
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
18,686
-29.48%
26,496
11.50%
23,763
9.19%
Cost of revenue
33,952
33,883
34,745
Unusual Expense (Income)
NOPBT
(15,266)
(7,387)
(10,982)
NOPBT Margin
Operating Taxes
185
78
27
Tax Rate
NOPAT
(15,451)
(7,465)
(11,009)
Net income
(6,716)
-65.73%
(19,599)
44.63%
(13,551)
41.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
24,909
38,380
BB yield
-27.17%
-57.05%
Debt
Debt current
532
3,077
Long-term debt
12,700
1,692
2,782
Deferred revenue
119
Other long-term liabilities
17,685
26,199
11,807
Net debt
(29,331)
(32,035)
(5,656)
Cash flow
Cash from operating activities
(10,465)
(11,885)
(8,916)
CAPEX
(6,464)
(555)
(489)
Cash from investing activities
(34,321)
(481)
3,548
Cash from financing activities
22,917
35,764
(1,050)
FCF
(17,851)
(16,965)
(10,521)
Balance
Cash
41,541
33,895
11,046
Long term investments
490
364
469
Excess cash
41,097
32,934
10,327
Stockholders' equity
(174,656)
(167,968)
(148,451)
Invested Capital
230,286
206,459
160,263
ROIC
ROCE
EV
Common stock shares outstanding
9,013
4,987
3,892
Price
10.17
-24.61%
13.49
-18.34%
16.52
-36.22%
Market cap
91,664
36.25%
67,276
4.63%
64,297
-36.14%
EV
62,333
35,241
58,641
EBITDA
(13,963)
(6,115)
(9,744)
EV/EBITDA
Interest
427
8,918
903
Interest/NOPBT